Carried by: BRAIN-TEAM
References:
Clinician(s): Claire EWENCZYK
Biologist(s): Jean-Madeleine DE SAINTE AGATHE, Florence RIANT

Presentation

Hereditary cerebellar ataxias, characterized by a progressive cerebellar syndrome in children or adults, are linked in half of cases to pathogenic nucleotide expansions, with the remainder showing considerable genetic heterogeneity. When clinical features point toward a specific diagnosis, targeted or panel testing is recommended; otherwise, GS can be performed as a first-line approach.

Care should be taken to detect the possible presence of a dominant disorder with variable expression in healthy relatives, revealing carrier status outside the scope of presymptomatic testing. The interpretation of GS, which is constantly evolving, detects SNVs and most CNVs, and is gradually incorporating mitochondrial DNA expansions and variants.

Criteria before considering a discussion in MDM-FMG

Complete clinical examination, brain MRI with T2*/SWI and sagittal T1 sequences

No GS proposed if:

  • Sporadic case AND age of onset > 60 years
  • Doubt about a non-genetic cause, possible or probable cerebellar MSA phenotype

 

In cases of clear clinical indication (major ataxia gene, ataxia with biological or radiological biomarkers)

Targeted sequencing or a panel is recommended (see flowchart)

(!) In the presence of sporadic ataxia with a rapidly unfavourable progression, severe dominant pathologies should be considered, the presentation of which may be sporadic due to anticipation (e.g. SCA2, SCA7, DRPLA) or incomplete penetrance/variable expressivity (e.g. PRNP).

In the absence of clear clinical guidance, for a familial form regardless of age of onset, or for a sporadic case with onset <60 years of age

  • GS is possible from the outset
  • In pairs/trios (solo submissions should be avoided)
    • Family history: collect DNA samples from affected relatives
    • Sporadic cases : prioritize DNA samples from unaffected relatives older than the age at onset in the index case

Genome Sequencing in diagnostic strategy

MDM cartography

MDM
Type of the MDM
City of the coordinator
Name, first name, and email of the contact

MDM Neurogenetics Paris Pitié

Regional, National Adult
Paris

MDM Neurogenetics Paris Trousseau

Regional, National Children
Paris

Diana RODRIGUEZ

diana.rodriguez@aphp.fr

Florence RENALDO

Florence.renaldo@aphp.fr 

Lydie BURGLEN

lydie.burglen@aphp.fr

MDM Neurogenetics Angers

Interregional
Angers

Christophe VERNY

chverny@chu-angers.fr

Virginie PICHON

virginie.pichon@chu-angers.fr

MDM Neurogenetics Bordeaux

Interregional
Bordeaux

Mathieu ANHEIM

mathieu.anheim@chru-strasbourg.fr

Christine TRANCHANT

christine.tranchant@chru-strasbourg.fr

Solène FRISMAND

s.frismand@chru-nancy.fr (Nancy)

Mathieu BEREAU

mbereau@chu-besancon.fr (Besançon)

Christel THAUVIN

christel.thauvin@chu-dijon.fr (Dijon)

Anne DOE DE MAINDREVILLE

adoedemaindreville@chu-reims.fr (Reims)

Quentin THOMAS

quentin.thomas@chu-dijon.fr

MDM Neurogenetics Montpellier

Interregional
Montpellier

MDM Neurogenetics Lille

Interregional
Lille